Hound Partners Reduces Stake in Bio-Rad Laboratories

Got story updates? Submit your updates here. ›

Hound Partners LLC, an investment management firm, decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 42.9% during the third quarter, according to a recent SEC filing. The firm now owns 103,963 shares of the medical research company's stock, valued at $29,150,000, making it Bio-Rad's 7th largest institutional investor.

Why it matters

The reduction in Hound Partners' stake in Bio-Rad Laboratories, a leading provider of life science research and clinical diagnostic products, signals a shift in the investment firm's portfolio allocation and confidence in the company's near-term prospects. This news may impact Bio-Rad's stock price and influence other institutional investors' decisions regarding the company.

The details

According to the filing, Hound Partners sold 77,973 shares of Bio-Rad Laboratories during the third quarter, reducing its total holdings to 103,963 shares. The investment firm now owns approximately 0.39% of Bio-Rad's outstanding shares. Bio-Rad Laboratories is a global provider of instruments, reagents, and consumables for various life science research and clinical diagnostic applications.

• Hound Partners decreased its holdings in Bio-Rad Laboratories during the 3rd quarter of 2026.